Quantcast
Home > Quotes > EVFM
EVFM

Evofem Biosciences, Inc. Common Stock (EVFM) Quote & Summary Data

$4.73
*  
0.02
0.42%
Get EVFM Alerts
*Delayed - data as of Jul. 16, 2019  -  Find a broker to begin trading EVFM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
10
Today's High / Low
$ 4.82 / $ 4.70
Share Volume
27,339
50 Day Avg. Daily Volume
161,529
Previous Close
$ 4.71
52 Week High / Low
$ 7.24 / $ 1.7918
Market Cap
219,500,399
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.31

Intraday Chart

Shares Traded

Share Volume:
27,339
50 Day Avg. Daily Volume:
161,529

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.07

Trading Range

The current last sale of $4.73 is 163.98% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.82 $ 7.24
 Low: $ 4.70 $ 1.7918

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. We exist to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs). We are leveraging our proprietary Multi-purpose Vaginal pH Regulator TM (MVP-R) platform to develop Amphora, which if approved will be the first on-demand and female controlled MVP-R birth control method in the U.S. Our MVP-R gel technology has both acid buffering and bio-adhesive properties and is designed to maintain an optimal vaginal pH of 3.5 to 4.5. This vaginal pH range is inhospitable to spermatozoa (sperm) as well as certain viral and bacterial pathogens associated with STIs, and it is integral to the survival of healthy bacteria in the vagina.  ... More ...  



Risk Grade

Where does EVFM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.70
Open Date:
Jul. 16, 2019
Close Price:
$ 4.73
Close Date:
Jul. 16, 2019


Consensus Recommendation

Analyst Info